Search For Scientific Publications - Meso Scale Discovery

Research laboratories and drug development companies around the world use MSD technology to analyze disease states through the characterization and quantification of biomarkers. We maintain a list of scientific journal articles that describe how MSD assays have been instrumental in providing highly sensitive, quantified, reproducible results.

Enter keywords to search all publications. To see a complete list of publications by research topic, select an area of interest.

Title	Journal	Year
NEW! Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.	Mol Cancer Ther	2011
Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. Qin JZ, Upadhyay V, Prabhakar B, Maker AV.	J Transl Med	2013
Associations of interleukin-6 with vegetative but not affective depressive symptoms in terminally ill cancer patients. Inagaki M, Akechi T, Okuyama T, Sugawara Y, Kinoshita H, Shima Y, Terao K, Mitsunaga S, Ochiai A, Uchitomi Y.	Support Care Cancer	2013
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK.	Br J Haematol	2013
Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Wen J, Zhao Y, Li J, Weng C, Cai J, Yang K, Yuan H, Imperato-McGinley J, Zhu YS.	Prostate	2013
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rúa SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT.	Ann Oncol	2013
Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc1638N/+ female mice. Huffman DM, Augenlicht LH, Zhang X, Lofrese JJ, Atzmon G, Chamberland JP, Mantzoros CS.	Cancer Prev Res	2013
Phase I study of Ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Ogura M, Hatake K, Tobinai K, Uchida T, Suzuki T, Terui Y, Yokoyama M, Maruyama D, Mori M, Jewell RC, Katsura K, Hotta T.	Jpn J Clin Oncol	2013
Phase II study evaluating 2 dosing schedules of oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.	PLoS One	2013
A human tRNA methyltransferase 9-like protein prevents tumour growth by regulating LIN9 and HIF1-α. Begley U, Sosa MS, Avivar-Valderas A, Patil A, Endres L, Estrada Y, Chan CT, Su D, Dedon PC, Aguirre-Ghiso JA, Begley T.	EMBO Mol Med	2013
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Fahrenholtz CD, Beltran PJ, Burnstein KL.	Mol Cancer Ther	2013
Phase I study of Dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B.	Clin Cancer Res	2013
Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, Loeb M, Bramson JL, Bowdish DM.	J Leukoc Biol	2013
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD.	Nature. 2013 Feb 14;494(7436):251-5.	2013
Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Fung FY, Li M, Breunis H, Timilshina N, Minden MD, Alibhai SM.	Leuk Res.	2013
A Potent Anti-HB-EGF Monoclonal Antibody Inhibits Cancer Cell Proliferation and Multiple Angiogenic Activities of HB-EGF. Sato S, Drake AW, Tsuji I, Fan J.	PLoS One	2012
Selective antagonist reveals the role of prostaglandin receptor EP2 in cancer cell proliferation, invasion and inflammation. Jiang J, Dingledine R.	J Pharmacol Exp Ther.	2012
Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase 2 study and biomarker analysis with Rilotumumab plus Mitoxantrone and Prednisone. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR.	Clin Cancer Res.	2012
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys. Wang B, Liang M, Yao Z, Vainshtein I, Lee R, Schneider A, Zusmanovich M, Jin F, O'Connor K, Donato-Weinstein B, Iciek L, Lavallee T, Roskos L.	J Pharm Sci.	2012
Monocytes and γδ T cells control the acute phase response to intravenous zoledronate: Insights from a phase IV safety trial. Welton JL, Morgan MP, Martí S, Stone MD, Moser B, Sewell AK, Turton J, Eberl M.	J Bone Miner Res.	2012
Impaired pten expression in human malignant peripheral nerve sheath tumours. Bradtmöller M, Hartmann C, Zietsch J, Jäschke S, Mautner VF, Kurtz A, Park SJ, Baier M, Harder A, Reuss D, von Deimling A, Heppner FL, Holtkamp N.	PLoS One	2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven BAK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD.	Clin Cancer Res.	2012
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two phase I trials in patients with advanced solid tumors. Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, Lorusso PM, Brachmann R, Tong RK, Yan Y, Watts R, Bai S, Hegde PS.	Clin Cancer Res.	2012
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG.	Proc Natl Acad Sci U S A.	2012
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.	Clin Cancer Res.	2012

Page 1 of 8

Next > Last >|